<DOC>
	<DOCNO>NCT02049294</DOCNO>
	<brief_summary>The purpose study investigate whether addition Omalizumab enable reduction dose prednisone patient asthma eosinophilic bronchitis . This double-blind placebo-controlled , 3-centre , randomized parallel group trial divide two sequential study period . Period 1 : After establish minimum dose prednisone maintain asthma control maintain sputum eosinophil &lt; 3 % , subject randomize either placebo Omalizumab 16 week ( either monthly 4 month every 2 week 4 month ) . Period 2 : standardise prednisone reduction interval 4-weeks clinical eosinophilic exacerbation bothersome steroid withdrawal effect . If patient exacerbation , treat prednisone . This patient continue Omalizumab placebo entire duration study continue phase steroid reduction .</brief_summary>
	<brief_title>Study Steroid Sparing Effect Xolair ( Omalizumab ) Patients With Persistent Eosinophilic Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Inclusion criterion 1 . Confirmed asthma within past 2 year ( 12 % bronchodilator reversibility PC20 methacholine le 8 mg/ml ) 2 . ACQ ≥1.5 sputum eos ≥3 % time randomization 3 . On ICS ( ≥ 1500 mcg fluticasone propionate equivalent ) without additional prednisone 4 . Total serum IgE ≥30 IU/L positive allergy skin prick test 5 . Age 18 75 year 6 . Ability provide inform consent Exclusion criterion 1 . Current smoker exsmokers great 20 pack year 2 . Comorbid diseases investigator 's opinion would make patient unsuitable participate study 3 . Currently Omalizumab previously treat Omalizumab 4 . Currently biologic therapy ( eg . Prolia ) 5 . Pregnancy lactation 6 . Post bronchodilator FEV1 le 50 % predict</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prednisone</keyword>
	<keyword>Eosinophils</keyword>
	<keyword>Immunoglobin E ( IgE )</keyword>
	<keyword>Asthma</keyword>
	<keyword>Bronchitis</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Allergy</keyword>
</DOC>